Physician profile
Curt Greeley
NPI 1093067332
$5,294.75
in general payments reported to CMS, 2019-2025
31 companies · $995 in 2025
The $995 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $17.40 · 2021: $577 · 2022: $1,086 · 2023: $812 · 2024: $1,193 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.05 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $783.01 | 2022-2025 | Idosetr, Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $713.15 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $450.07 | 2019-2025 | Hydrus Microstent, Clareon, Argos |
| Rxsight INC | $404.27 | 2021-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $385.64 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $313.30 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $307.53 | 2019-2021 | |
| Biotissue Holdings INC. | $252.48 | 2022-2025 | |
| Nova Eye, INC. | $204.64 | 2025 | |
| Mallinckrodt Hospital Products INC. | $176.32 | 2022 | |
| Allergan, INC. | $158.89 | 2021 | |
| Notal Vision, INC. | $157.07 | 2022 | |
| Amgen INC. | $144.04 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Astellas Pharma US INC | $118.37 | 2024 | Izervay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $96.17 | 2022-2024 | Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $62.03 | 2019 | |
| Dompe US, INC. | $55.02 | 2023-2025 | Oxervate |
| Thea Pharma INC. | $50.71 | 2022-2023 | Iyuzeh |
| Horizon Therapeutics Plc | $48.09 | 2021-2022 | |
| Carl Zeiss Meditec, INC. | $47.57 | 2019 | |
| Sight Sciences, INC. | $44.98 | 2019-2025 | Tearcare System |
| Oyster Point Pharma, INC. | $31.76 | 2022-2023 | Tyrvaya |
| Tearlab Corp | $30.86 | 2022 | |
| Lumibird Medical INC. | $28.20 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $23.29 | 2019 | |
| Coopervision INC. | $20.16 | 2021 | |
| Akorn, INC. | $17.40 | 2020 | |
| Harrow Eye, LLC | $17.01 | 2024 | Vevye |
| Mallinckrodt Enterprises LLC | $15.04 | 2019 | |
| Staar Surgical Company | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Greeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.